Results 31 to 40 of about 149,361 (217)

Busulfan in Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation, 2009
The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of ...
Ciurea, Stefan O., Andersson, Borje S.
openaire   +2 more sources

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation

Frontiers in Immunology, 2018
Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. However, patients who undergo HSCT acquire a state of immunodeficiency that causes significant mortality. Reconstitution of thymic function
Luis Klaus A. da Rocha, Samar Freschi de Barros, Francine Bandeira, Alexia Bollini, Lucia Helena de A. Testa, Anderson João Simione, Marina de O. e Souza, Lilian P. Zanetti, Leila Cibele S. de Oliveira, Ana Claúdia F. dos Santos, Mair Pedro de Souza, Vergílio Antônio R. Colturado, Jorge Kalil, Clarisse M. Machado, Luiza Guilherme   +14 more
doaj   +1 more source

Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients

, 2013
Despite the availability of new antifungal compounds, invasive fungal infection remains a significant cause of morbidity and mortality in children and adults undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Allogeneic HSCT recipients
Lehrnbecher, Thomas, Thomas eLehrnbecher, Schmidt, Stanislaw, Thomas eKlingebiel, Tramsen, Lars, Lars eTramsen, Klingebiel, Thomas, Stanislaw eSchmidt   +7 more
core   +1 more source

Comparison between different reduced intensity conditioning regimens in AML/MDS patients in a Latin American center of adult stem cell transplantation

Hematology
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for several hematological diseases. Prospective and retrospective studies have associated myeloablative conditioning regimens with increased non-relapse ...
José Salinas, Yorman Flores, Patricio Rojas, Catherine Gutierrez, Marcela Vidal, Verónica Jara, James Campbell, María José García, Vicente Sandoval, Maximiliano Vergara, Mauricio Ocqueteau, Felipe Palacios, Mauricio Sarmiento   +12 more
doaj   +1 more source

Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Pharmaceuticals, 2022
Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT).
Daniel N. Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu, Esther Carcelero, Joan Ramón Roma, Noemí Llobet, Jordi Arcarons, María Suárez-Lledó, Nuria Martínez, Alexandra Pedraza, Ariadna Domenech, Laura Rosiñol, Francesc Fernández-Avilés, Álvaro Urbano-Ispízua, Montserrat Rovira, Mercè Brunet, Carmen Martínez   +18 more
doaj   +1 more source

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor

, 2013
Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
Dembowsky, K., Dembowsky, Klaus, Romagnoli, B., G Spohn, Karpova, Darja, Patel, K., Chevalier, E., Levesque, J. P., E Chevalier, D Karpova, Patel, Kalpana, Spohn, Gabriele, Romagnoli, Barbara, Schulz, M., Wiercinska, Eliza, Chevalier, Eric, H Bonig, K Dauber, E Wiercinska, J P Levesque, Schulz, Miriam, Chudziak, D., K Dembowsky, Dauber, Katrin, Karpova, D., B Romagnoli, A R Pettit, Wiercinska, E., D Chudziak, Levesque, Jean-Pierre, Bönig, Halvard-Björn, Spohn, G., Pettit, Allison R., M Schulz, K Patel, Bonig, H., Pettit, A. R., Chudziak, Doreen, Dauber, K.   +38 more
core   +1 more source

Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective

Frontiers in Oncology
IntroductionIn resource-limited countries, access to advanced therapies like CAR T-cell therapy is often unattainable. Clinical trials face challenges, with pediatric populations frequently excluded or experiencing significant delays. This highlights the
Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, Valéria Cortez Ginani, Camila Noronha Santos, Milena Reis Santos de Oliveira, Anna Beatriz Willemes Batalha, Gabriella Sayuri de Alencar, Edna Harumi Goto, Juliana Francielle Marques, Marcia Puato Vieira Pupim, Adriana Seber, Adriana Seber   +13 more
doaj   +1 more source

Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation

, 2012
Background: Reconstitution of cytomegalovirus-specific CD3+CD8+ T cells (CMV-CTLs) after allogeneic hematopoietic stem cell transplantation (HSCT) is necessary to bring cytomegalovirus (CMV) reactivation under control. However, the parameters determining
Matthias Eder (21135), Borchers, Sylvia, Benno Wölk, Sylvia Borchers, Arnold Ganser, Pabst, Brigitte, Mischak-Weissinger, Eva Maria, Michael Stadler, Elke Dammann, Andrea Jarisch, Lehrnbecher, Thomas, Arnold Ganser (4454), Eva M. Weissinger (111202), Meral Yildiz, Schneider, Gisbert, Matthias Eder, Peter Bader, Melanie Bremm (111153), Koehl, Ulrike, Thomas Klingebiel, Michael Stadler (111171), Ulrike Koehl, Hans Martin, Benno Wölk (111163), Stadler, Michael, Thomas Lehrnbecher, Sylvia Borchers (111150), Wölk, Benno, Hans Martin (111179), Meral Yildiz (111168), Dammann, Elke, Thomas Klingebiel (111191), Brigitte Pabst (111160), Bader, Peter, Eder, Matthias, Jarisch, Andrea, Brigitte Pabst, Gisbert Schneider, Elke Dammann (111158), Gisbert Schneider (17096), Ulrike Koehl (111209), Thomas Lehrnbecher (111156), Klingebiel, Thomas, Esser, Ruth, Eva M. Weissinger, Ruth Esser (111165), Ganser, Arnold, Yildiz, Meral, Melanie Bremm, Peter Bader (111174), Eva M Weissinger, Bremm, Melanie, Andrea Jarisch (111185), Ruth Esser, Weissinger, Eva M., Köhl, Ulrike, Martin, Hans   +56 more
core   +1 more source

Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico

Frontiers in Oncology
BackgroundPrecursor B-cell acute lymphoblastic leukemia (pre-B ALL) is the most common pediatric cancer worldwide, with cure rates exceeding 85% in high-income countries.
Alberto Olaya-Vargas, Alberto Olaya-Vargas, Haydee Salazar-Rosales, Yadira Melchor-Vidal, Martín Pérez-García, Annecy Herver-Olivares, Gerardo López-Hernández, Nideshda Ramírez-Uribe, Nideshda Ramírez-Uribe, Cesar Galván-Díaz, Irlanda Campos-Pérez, Pilar Cubria-Juárez, Angeles Del Campo-Martínez, Norma López-Santiago, Rocio Cárdenas-Cardos, Rocio Cárdenas-Cardos, Cesar Cárdenas-Pérez Gallardo, Ignacio Mora-Magaña, Jaime Shalkow-Klincovstein   +18 more
doaj   +1 more source

Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes

OncoImmunology, 2017
Use of high-dose, post-transplant cyclophosphamide (PTCy) results in low rates of graft-versus-host-disease (GVHD) and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure.
Yu Wang, Ying-Jun Chang, Lu Chen, Lan-Ping Xu, Zhi-Lei Bian, Xiao-Hui Zhang, Chen-Hua Yan, Kai-Yan Liu, Xiao-Jun Huang   +8 more
doaj   +1 more source